东莞证券股份有限公司 关于特一药业集团股份有限公司 使用 2023 年度以简易程序向特定对象发行股票部分闲置募集资金 进行现金管理的核查意见 东莞证券股份有限公司（以下简称"东莞证券"或"保荐机构"）作为特一药业集 团股份有限公司（以下简称"特一药业"或"公司"）2023年度以简易程序向特定对象 发行股票的保荐机构，根据《上市公司募集资金监管规则》《深圳证券交易所股票上市 规则》《深圳证券交易所上市公司自律监管指引第1号——主板上市公司规范运作》等 法律法规的有关规定，对特一药业拟使用2023年度以简易程序向特定对象发行股票部分 闲置募集资金进行现金管理的情况进行了审慎核查，并出具本核查意见。核查情况如下： 一、募集资金基本情况 经中国证券监督管理委员会《关于同意特一药业集团股份有限公司向特定对象发行 股票注册的批复》（证监许可【2023】1987号）同意注册，公司向9家特定投资者发行 人民币普通股20,146,514股，发行价格为每股13.65元。截至2023年9月14日，本公司实 际以简易程序向特定对象发行人民币普通股（A股）20,146,514股，募集资金总额 274,999,916.10元，扣除承销费 ...

东莞证券股份有限公司 关于特一药业集团股份有限公司 使用 2023 年度以简易程序向特定对象发行股票部分闲置募集资金暂时补 充流动资金的核查意见 东莞证券股份有限公司（以下简称"东莞证券"或"保荐机构"）作为特一药业集 团股份有限公司（以下简称"特一药业"或"公司"）2023 年度以简易程序向特定对象 发行股票的保荐机构，根据《深圳证券交易所股票上市规则》《深圳证券交易所上市公 司自律监管指引第 1 号——主板上市公司规范运作》和《上市公司募集资金监管规则》 等有关规定，东莞证券对公司使用 2023 年度以简易程序向特定对象发行股票部分闲置 募集资金暂时补充流动资金的情况进行了认真、审慎核查。核查的具体情况如下： 一、募集资金的基本情况 | 序 | 项目名称 | 融资项目名称 | | 调整后拟投 入募集资金 | 募集资金 累计投入 | 累计投 入比例 | 项目预定可使 | | --- | --- | --- | --- | --- | --- | --- | --- | | 号 | | | | （万元） | 金额 （万元） | （%） | 用状态日期 | | 1 | 补充流动 资金 | 2023 | 年度以简 ...

Core Insights - The stock price of Te Yi Pharmaceutical (002728) closed at 9.47 yuan, with a 0.74% increase and a turnover rate of 7.5% as of August 12, 2025 [1] - The company reported a total revenue of 295 million yuan for Q1 2025, representing a year-on-year growth of 79.29%, and a net profit of 31.57 million yuan, up 244.82% year-on-year [1] Financial Performance - Total revenue for Q1 2025: 295 million yuan, up 79.29% year-on-year [1] - Net profit: 31.57 million yuan, up 244.82% year-on-year [1] - Non-recurring net profit: 31.71 million yuan, up 255.28% year-on-year [1] - Current ratio: 2.023, Quick ratio: 1.305, Debt-to-asset ratio: 19.06% [1] Market Activity - Main capital inflow: 10.01 million yuan, accounting for 3.74% of the total transaction amount [1] - Large single orders net inflow: 9.84 million yuan, accounting for 3.67% of the total transaction amount [1] - Small orders net outflow: 20.20 million yuan, accounting for 7.54% of the total transaction amount [1] Company Overview - Te Yi Pharmaceutical Group Co., Ltd. was established in 2002 and is located in Jiangmen City, primarily engaged in the pharmaceutical manufacturing industry [2] - Registered capital: 5.13 billion yuan, paid-in capital: 2 billion yuan [2] - The company has invested in 8 enterprises and participated in 466 bidding projects [2]

市场表现上，送转方案公布首日，股价上涨的有11只，股价下跌的有2只。跌幅较大的有森麒麟、康普 化学等。送转方案公布以来股价上涨的有10只，涨幅较大的有朗鸿科技、乔治白等，分别上涨 17.76%、15.22%；股价下跌的有3只，跌幅最大的是康普化学，累计下跌4.56%。 【纠错】 【责任编辑:刘帅 】 证券时报•数据宝统计显示，截至3月14日，66家公司披露了2023年度分配方案，其中分配方案中包含送 转的公司有13家。从送转方案来看，其中，送转比例居前的有安孚科技、特一药业、森麒麟等，安孚科 技10送转4.5股，特一药业10送转4股，森麒麟10送转4股。 统计显示，公布送转方案的13家公司中，在进行送转的同时全部搭配了现金分红。目前推出纯派现的公 司也有53家。 业绩方面，公布送转方案的公司中，有13家公司已经披露了年报或业绩快报，净利润同比增长的有11 家，净利润增幅居前的有帝科股份、锋尚文化、昊海生科等，分别增长2336.51%、813.92%、 130.58%。净利润同比下降的有2家，净利润降幅居前的有德明利、广厦环能等，净利润分别下降 62.97%、4.28%。 按所属板块来看，公布送转方案的公司中， ...

通过天眼查大数据分析，特一药业集团股份有限公司共对外投资了8家企业，参与招投标项目462次，知 识产权方面有商标信息59条，专利信息76条，此外企业还拥有行政许可618个。 来源：金融界 特一药业最新一期业绩显示，截至2025一季报，公司营业总收入2.95亿元、同比增长79.29%，归属净利 润3156.73万元，同比增长244.82%，扣非净利润3170.69万元，同比增长255.28%，流动比率2.023、速动 比率1.305、资产负债率19.06%。 天眼查商业履历信息显示，特一药业集团股份有限公司，成立于2002年，位于江门市，是一家以从事医 药制造业为主的企业。企业注册资本51256.5434万人民币，实缴资本20000万人民币。公司法定代表人 为许荣煌。 金融界消息 截至2025年8月4日收盘，特一药业（002728）报收于9.91元，上涨4.54%，换手率18.04%， 成交量67.92万手，成交金额6.60亿元。 资金流向方面，今日主力资金净流入3310.81万元，占比成交额5.02%。其中，超大单净流入74.74万 元、占成交额0.11%，大单净流入3236.08万元、占成交额4.9%，中单 ...

Group 1 - The legal representative of Te Yi Pharmaceutical Group Co., Ltd. has changed from Xu Danqing to Xu Ronghuang [1] - Te Yi Pharmaceutical was established in 2002 and is located in Jiangmen City, primarily engaged in the pharmaceutical manufacturing industry [1] - The company has a registered capital of 5,125.65434 million RMB and a paid-in capital of 2,000 million RMB [1] Group 2 - Te Yi Pharmaceutical has invested in 8 enterprises and participated in 462 bidding projects [1] - The company holds 59 trademark registrations and 76 patent registrations [1] - Te Yi Pharmaceutical possesses 618 administrative licenses [1]

Core Viewpoint - The announcement details the completion of business registration changes and the issuance of a new business license for Te Yi Pharmaceutical Group Co., Ltd, following the approval of changes to the company's registered capital and amendments to its articles of association by the board and shareholders [1][4]. Group 1: Business Registration Changes - The company held meetings on June 30, 2025, and July 16, 2025, to approve the changes to registered capital and amendments to the articles of association [1]. - The company has completed the business registration change and obtained a new business license from the Jiangmen Market Supervision Administration [1]. Group 2: Company Information Post-Change - The company's registered capital is now RMB 51,256.5434 million [2]. - The company is classified as a joint-stock company (listed, natural person investment or control) [2]. - The legal representative is Xu Ronghuang, and the company is located at No. 9, 11 Changxing Road, Taicheng, Taishan City [2]. - The business scope includes pharmaceutical manufacturing, health product production, wholesale of medical devices and daily necessities, technical services, and property leasing [2].

Core Viewpoint - The company has successfully completed the registration change and amendment of its articles of association, reflecting an increase in registered capital and a change in the legal representative [1] Group 1: Company Registration Changes - The company held the 33rd meeting of the fifth board and the second extraordinary general meeting of 2025 on June 30 and July 16, 2025, respectively, to approve the proposal for changing the registered capital and amending the articles of association [1] - The registered capital increased from 51,078.8782 million RMB to 51,256.5434 million RMB [1] - The legal representative changed from Xu Danqing to Xu Ronghuang [1] Group 2: Business License Information - The company’s business license has been updated to reflect the new registered capital of 51,256.5434 million RMB [1] - The company is classified as a joint-stock company (listed, natural person investment or control) [1] - The company’s establishment date is May 23, 2002, and its business scope includes pharmaceutical manufacturing, health product production, and medical equipment wholesale [1]

Group 1 - The core viewpoint of the news is that Te Yi Pharmaceutical (002728) has shown significant financial growth in its latest quarterly report, with a notable increase in revenue and net profit [1] - As of August 1, 2025, Te Yi Pharmaceutical's stock price closed at 9.48 yuan, reflecting a 2.38% increase, with a trading volume of 545,600 hands and a transaction amount of 520 million yuan [1] - The company reported total revenue of 295 million yuan for Q1 2025, representing a year-on-year growth of 79.29%, and a net profit attributable to shareholders of 31.57 million yuan, up 244.82% year-on-year [1] Group 2 - Te Yi Pharmaceutical has made investments in 8 companies and participated in 459 bidding projects, indicating active engagement in business expansion [2] - The company holds 59 trademark registrations and 76 patents, showcasing its commitment to intellectual property development [2] - Te Yi Pharmaceutical has obtained 618 administrative licenses, reflecting its compliance and operational capabilities in the pharmaceutical industry [2]

证券代码：002728 证券简称：特一药业 公告编号：2025-052 特一药业集团股份有限公司 关于完成工商变更登记并换发营业执照的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 特一药业集团股份有限公司（以下简称"公司"）分别于 2025 年 6 月 30 日、2025 年 7 月 16 日召开了第五届董事会第三十三次会议和 2025 年第二次临时股东会，审议通 过了《关于变更公司注册资本及修订＜公司章程＞并提请股东会授权董事会办理相关工 商备案事项的议案》，具体内容详见公司分别于 2025 年 7 月 1 日、2025 年 7 月 17 日披 露于巨潮资讯网的《关于变更公司注册资本及修订<公司章程>的公告》《2025 年第二次 临时股东会决议公告》。 一、本次工商变更登记事项 | 登记事项 | 变更前 | 变更后 | | --- | --- | --- | | 法定代表人 | 许丹青 | 许荣煌 | | 注册资本 | 51078.8782 万元 | 51256.5434 万元 | 除上述变更外，公司《营业执照》其他登记事项不变。 二、本次工商登记变 ...